The Molecular Basis of Calcium and Phosphorus Inherited Metabolic Disorders

Anna Papadopoulou *, Evangelia Bountouvi and Fotini-Eleni Karachaliou

Third Department of Pediatrics, University General Hospital “ATTIKON”, Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece; boudouvi@yahoo.gr (E.B.); fenkar1@hotmail.com (F.-E.K.)

* Correspondence: anpapado@med.uoa.gr; Tel.: +30-210-583-1911

Abstract: Calcium (Ca) and Phosphorus (P) hold a leading part in many skeletal and extra-skeletal biological processes. Their tight normal range in serum mirrors their critical role in human well-being. The signalling “voyage” starts at Calcium Sensing Receptor (CaSR) localized on the surface of the parathyroid glands, which captures the “oscillations” of extracellular ionized Ca and transfers the signal downstream. Parathyroid hormone (PTH), Vitamin D, Fibroblast Growth Factor (FGF23) and other receptors or ion-transporters, work synergistically and establish a highly regulated signalling circuit between the bone, kidneys, and intestine to ensure the maintenance of Ca and P homeostasis. Any deviation from this well-orchestrated scheme may result in mild or severe pathologies expressed by biochemical and/or clinical features. Inherited disorders of Ca and P metabolism are rare. However, delayed diagnosis or misdiagnosis may cost patient’s quality of life or even life expectancy. Unravelling the thread of the molecular pathways involving Ca and P signaling, we can better understand the link between genetic alterations and biochemical and/or clinical phenotypes and help in diagnosis and early therapeutic intervention.

Keywords: Calcium Sensing Receptor (CaSR); parathyroid hormone (PTH); vitamin D; vitamin D receptor (VDR); Fibroblast Growth Factor 23 (FGF23); calcium metabolism; phosphorus metabolism; rare diseases

1. Introduction

The investigation of the genetic basis of Calcium (Ca) and Phosphorus (P) metabolic inherited disorders brings to light, piece by piece, precious information regarding the complexity and function of a huge molecular circuit, in which these minerals play a leading or supporting role, depending on the cellular demands. Although being recognized for their involvement in skeletal formation and maintenance, Ca and P participate in many biological processes. Their critical role for human health is mirrored by their serum near-constant concentrations, achieved by a well-orchestrated homeostatic system, which comprises the parathyroid glands, the intestine, the kidneys and the skeleton. To date, inherited metabolic disorders of Ca/P metabolism are mainly rare, presenting with a wide range of clinical manifestations, some of latter being common among diseases of different etiologies. Therefore, they require different therapeutic approaches. In this review, we provide an overview of the Ca/P signalling pathway and discuss the genetic basis of known inherited diseases associated with extracellular Ca sensing mechanisms, Parathyroid hormone (PTH) production and action, Vitamin D metabolism and Fibroblast Growth Factor 23 (FGF23) synthesis and function.
2. Calcium and Its Partners

Calcium (Ca) is the most abundant mineral in human bone tissue and critically important to human health [1]. It participates in bone formation and maintenance, muscle contraction, neuron depolarization, blood coagulation and intracellular processes, including signal transduction, production and secretion of hormones. Almost 1000 mg/24 h of Ca enter the body of an average adult, depending on the quantity of milk and other dairy products consumed. The recommended Ca intake for infants is 200 mg/24 h which gradually increases in childhood, while the highest requirements are noted during adolescence and individuals over 50 years old [2]. About 40% of dietary Ca is absorbed from the gastrointestinal tract via a paracellular pathway and an active transcellular pathway both potentially regulated by 1,25(OH)₂D₃ [3-5]. Half of the absorbed Ca leaves the body in urine and feces. There are 3 major pools of Ca in the body: (a) Within cells, (b) blood and extracellular fluid and (c) bones, where the vast majority of body Ca is stored.

Within bones, 99% of Ca is found in the mineral phase as hydroxyapatite [Ca₁₀(PO₄)₆(OH)₂], but the remaining 1% is in a pool that can rapidly exchange with extracellular Ca to ensure the Ca homeostasis. The skeleton turns over about 250 mg/day of Ca, while approximately 10,000 mg/day is filtered at the glomerulus and most is reabsorbed by the renal tubules [6]. Approximately half of Ca in blood and extracellular fluid is bound to proteins (~45% albumin) or complexed with ions (~10%), including phosphates and ~45% circulates as a free, ionized fraction (Ca²⁺). The biologic effect of Ca is determined by Ca²⁺ rather than the total Ca. The serum level of Ca is closely regulated with a normal total Ca of 2.2–2.7 mmol/L (8.8–10.8 mg/dL) and a normal Ca²⁺ of 1.12–1.23 mmol/L (4.8–4.92 mg/dL). The concentration of Ca²⁺ in blood and extracellular fluid is normally almost invariant at approximately 1 mM, or 1000 to 10,000 times the basal concentration of Ca²⁺ within cells. Deviations above or below the normal range, frequently, lead to serious diseases. Contrary to the tight serum normal range, intracellular Ca²⁺ concentrations fluctuate greatly, from roughly 100 nM to greater than 1 μM, due to release from cellular stores or influx from extracellular fluid. These fluctuations assign Ca direct or indirect responses to both cellular needs and serum Ca homeostasis [1].

Maintaining constant Ca²⁺ concentrations in blood requires the collaboration of primary regulating hormones, PTH and 1,25(OH)₂D₃, receptors and enzymes involved in Ca metabolic pathway. Being the first player of this cascade, the Calcium Sensing Receptor (CaSR) captures the oscillations of serum Ca²⁺ and, along with the activity of the parathyroid glands, regulate PTH synthesis and secretion. Next, PTH acts on the target organs, mainly on the kidneys and bones through its receptor and indirectly on the intestine via regulation of 1,25(OH)₂D₃. Defects of the molecular components of this circuit are frequently the cause of genetic inherited disorders.

2.1. Calcium Sensing receptor

CaSR comprises a fundamental contributor to extracellular Ca²⁺ homeostasis, modulating the synthesis/secretion of PTH in an inverse manner, reducing Ca²⁺ renal reabsorption and interfering in bone development and lactation [7]. It binds to various physiological ligands and is expressed in many calcitropic and non-calcitropic tissues, yet more abundantly in cells of the parathyroid glands and the renal tubular cells. The receptor is a member of family C G-protein coupled receptors (GPCRs) characterized by a large extracellular N-terminal domain responsible for ligand binding and receptor dimerization, seven transmembrane segments and an intracellular C-terminal domain that couples to G proteins and other signal transduction molecules [8]. Understanding how Ca and other extracellular cations interact with the extracellular portion of the CaSR is not well-understood. It has been proposed that the binding of Ca²⁺ or other compatible ligands at the cleft between the Venus Flytrap (VFT) lobes in the extracellular domain induces rotation along the dimer interface (Figure 1) [9,10]. VFT consists of a large, nutrient-binding bilobed domain, located in the N-terminus part of the protein, adjacent to the C-side of signal peptide.
Such a conformational change could, thus, alter the spatial configuration of the membrane-spanning portion of the receptor and modulate signal transduction [8,11,12].

In the parathyroid gland, CaSR activation induces Gαq11-mediated activation of phospholipase C (PLC), increases inositol 1,4,5-trisphosphate (IP3) and leads to intracellular Ca²⁺ mobilization, which acts as a secondary messenger of different cell-dependent actions, such as PTH synthesis regulation. PTH acts through its receptor PTHR1 at target organs (kidney), and activates via G proteins, the axis GαS–adenylyl cyclase–cAMP–protein kinase A (PKA). The produced cAMP acts as cellular second messenger promoting the transcription of target genes. PTH promotes 1,25(OH)₂D₃ synthesis via CYP27B1 activation and inhibits Pi reabsorption by inhibiting NaPi-2c (and NaPi-2a) cotransporter. FGF23 mediates its actions through its receptor FGFR1 and inhibits 1,25(OH)₂D₃ renal synthesis and Pi reabsorption while it promotes 1,25(OH)₂D₃ catabolism via activation of CYP24A1. Genetic defects associated with alterations of the proteins illustrated in this scheme are marked in the respective boxes.
heterogeneity among parathyroid cells could account for the variations in the response of patients with primary or secondary hyperparathyroidism to standardized intravenous infusion of calcium [16].

2.2. Parathyroid Hormone

Parathyroid Hormone (PTH) is initially synthesized as a prepropeptide, which, after 2 proteolytic cleavages gives rise to the active 84-amino-acid peptide (intact PTH, iPTH) [17]. Several factors regulate its biosynthesis such as Ca\(^{2+}\), 1,25(OH)\(_2\)D\(_3\) and Pi. The circulating half-life of the molecule is less than 5 min. Along with iPTH, a heterogeneous collection of peptides corresponding to the amino (N-), middle and carboxyl (C-) regions of the molecule are produced. The C-terminal PTH fragments, are present in the circulation in large amounts and being recognizable by specific receptors (CPTHRs) [18]. Normally, these fragments circulate in blood at concentrations higher than that of iPTH, and at much higher levels in renal failure. The normal levels of serum iPTH range between 10.0 to 60.0 pg/mL [19].

The principal role of PTH is to increase serum Ca\(^{2+}\) concentrations by acting upon its receptor which is highly expressed in bone and kidney. The classic PTH receptor is a member of the GPCR family. It is designated type 1 PTH/PTHrP receptor (PTHR1) as it recognizes the amino-terminus of PTH and the homologous terminus of the parathyroid hormone-related protein (PTHRP) with similar or indistinguishable affinity [18]. This receptor, via G proteins, can activate at least two signal transduction pathways: G\(\alpha\)-adenylyl cyclase–cAMP–protein kinase A (PKA), where cAMP is the cellular second messenger, and G\(\alpha\)-phospholipase C (PLC) \(\beta\)-IP\(_3\)-cytoplasmic Ca\(^{2+}\)-protein kinase C pathway protein kinase C (PKC). The direction of the regulation appears to depend on cell type and PTH concentration [20].

In the kidney, PTH enhances reabsorption of Ca\(^{2+}\), predominantly in the distal tubule and the thick ascending limb resulting in minimal losses of Ca\(^{2+}\) in urine. Furthermore, in the renal proximal tubule PTH inhibits the reabsorption of P [19]. In bone, PTH, via its receptor expressed on osteoblasts and stromal cells, has been considered to have either a catabolic or anabolic effect [21]. The anabolic effect is exerted by low and intermittent concentrations of PTH, and has been applicable to osteoporosis treatment by daily injections of PTH. On the other hand, high levels of PTH, as in primary and secondary hyperparathyroidism, lead to bone resorption. Finally, PTH promotes intestinal Ca absorption indirectly by up regulating renal 25-vitamin D 1α-hydroxylase, the enzyme responsible for converting 25(OH)D in its active form.

2.3. Vitamin D

Vitamin D is one of the most important orchestrates of Ca homeostasis. It is a fatsoluble secosteroid formed mostly in human skin by exposure to sunlight, while a small percentage comes directly from diet [22,23]. Vitamin D3 is produced photochemically in the skin from the precursor molecule 7-dihydroxycholesterol (7-DHC). Vitamin D2 (ergocalciferol), the exogenous form of vitamin D, is produced by ultraviolet irradiation of the plant sterol ergosterol and is acquired through the diet. The amount of Vitamin D recommended by the US Institute of Medicine, is 400–800 IU/day, depending on the ethnicity, the age and the socioeconomic status of the population [24,25]. Furthermore, under physiological particular conditions, such as pregnancy and lactation, vitamin D doses are adjusted [24,26,27].

Both vitamin D3 and vitamin D2, must be further metabolised to be active. Their first hydroxylation at the carbon in position 25 produces 25(OH)D or calcidiol [28] (Figure 2). This conversion takes place in the liver by cytochrome P450 proteins, the mitochondrial 25-hydroxylase, CYP27A1, and the microsomal 25-hydroxylase, CYP2R1. Mutations in the genes encoding for the conversion enzymes are associated with rare inherited diseases such as cerebrotendinous xanthomatosis (MIM 213700) [29] (gene CYP27A1) without a
defected vitamin D metabolism-and Vitamin D Hydroxylation Deficient Rickets type 1B (VDDR1B; MIM 60081) (gene CYP2R1) [30].

While, 25(OH)D is the main circulating metabolite of vitamin D with a half-life of several weeks and its concentration in serum reflects the vitamin D stores in man. Appropriate vitamin D levels are essential for proper bone health in early life and reducing the risk of developing osteoporosis later. The demarcation line between sufficient and insufficient vitamin D status is not very clearly defined. The Endocrine Society, defines as deficient, vitamin D status 25(OH)D serum levels in adults less than 20 ng/mL (<50 nmol/L); while the UK Scientific Advisory Committee on Nutrition (SACN) less than 11 ng/mL (25 nmol/L) and other agencies less than 13 ng/mL (30 nmol/L) [31].

In the proximal tubule of the kidney 25(OH)D is further metabolized in 1,25 (OH)₂D₃ by 1α-hydroxylase (gene: CYP27B), yielding the biologically active form of vitamin D. Its half-life is a few hours. Several types of cells, including cells from the decidua and placenta, keratinocytes, activated macrophages, prostatic and colon epithelial cells, and vascular endothelial and smooth muscle cells are known to express 1α-hydroxylase and produce 1,25(OH)₂D₃ [32]. The synthesis of 1,25(OH)₂D₃ is tightly regulated; stimulated by PTH and inhibited by high concentrations of Ca, P, FGF23 and 1,25(OH)₂D₃ itself. The normal serum concentration of 1,25(OH)₂D₃ is ranged between 20–60 pg/mL. Mutations in CYP27B are associated with Vitamin D Hydroxylation Deficient Rickets, type 1A (VDDR1A) (MIM 264700) [33]. The phenotypic and laboratory features of this disorder are

Figure 2. Schematic illustration of Vitamin D metabolism. Vitamin D resulting either from cutaneous synthesis or, directly from the diet, is metabolized to 25(OH)D by the liver mitochondrial 25-hydroxylase (CYP27A1), and the microsomal 25-hydroxylase (CYP2R1). 25(OH)D is further metabolized to 1,25(OH)₂D, by the renal 1α-hydroxylase (CYP27B1). 1,25(OH)₂D may exerts its biologic effects through its receptor (VDR) or be catabolized by the 24-hydroxylse (CYP24A1). The net effect of 1,25(OH)₂D on Ca/P metabolism is the increase in Ca/P serum concentration. PTH on the other hand, ensures increased levels of sCa and decreased levels of sPi. In this figure, the genetic defects associated with alterations in the Vitamin D metabolic pathway are marked in boxes, next to the respective enzymes.
presented in detail below. Moreover, in the kidney, the enzyme 25-hydroxyvitamin D-24-hydroxylase, CYP24A1 converts 1,25(OH)\(_2\)D\(_3\) to 1,24,25-trihydroxyvitamin D in a series of catabolic steps that lead to the inactivation of 1,25(OH)\(_2\)D\(_3\) [34,35]. The gene transcription is mostly regulated by 1,25(OH)\(_2\)D and PTH while mutations in CYP24A1 are associated with Idiopathic Infantile Hypercalcemia type 1 (MIM 143880) [36].

While, 1,25-dihydroxy vitamin D, is transported in blood, bound to specific vitamin D-binding protein and, to a lesser amount, to albumin. Vitamin D mediates its biological effects through its own member of the nuclear hormone receptor superfamily, the vitamin D receptor (VDR) [37,38]. VDR is expressed in most organs including the intestine, bone, kidney, and parathyroid gland cells, as well as in brain, heart, skin, gonads, prostate and the breast. It is a transcription factor, and a member of the ligand-activated receptor superfamily that plays a major role in Ca metabolism. The receptor binds many vitamin D metabolites, and 1,25(OH)\(_2\)D\(_3\) has the highest affinity. Upon activation by 1,25(OH)\(_2\)D\(_3\), the VDR complexes with other nuclear hormone receptors and binds to specific DNA sequences called vitamin D response elements (VDRE) in the promoter of hormone-responsive genes, such as osteocalcin, p21, 24-hydroxylase, PTH [39]. It is estimated that VDR activation may regulate directly and/or indirectly the expression of a very large number of genes (0.5–5% of the total human genome, i.e., 100–1250 genes) [40].

The principal effect of 1,25(OH)\(_2\)D\(_3\) is the stimulation of intestinal absorption of Ca\(^{2+}\) from the luminal contents of the intestine, primarily in the jejunum and ileum, and its transfer into the circulation [41]. Ca enters the intestine epithelial cells through the TRPV6 channel, binds to calbindin (CaBP-9k), and passes to the extracellular space and blood circulation, via an ATP-dependent Ca\(^{2+}\)-ATPase (PMCA1b). The expression of these genes is regulated by 1,25(OH)\(_2\)D\(_3\). In the kidney, Ca\(^{2+}\) absorption and excretion by the epithelial renal cells is mediated by the TRPV5 channel, calbindin (CaBP-28k) and PMCA1b, in a way similar to that in the intestine. These proteins are also under the control of 1,25(OH)\(_2\)D\(_3\) [42]. Within the bone tissue, it seems that the response of bone cells, stimulated by 1,25(OH)\(_2\)D\(_3\), is probably correlated to their maturation and differentiation stage [43]. It promotes the differentiation of the mesenchymal osteoblast precursors to mature osteoblasts via the activation of LRP5 gene and the suppression of RUNX2 gene. Moreover, it stimulates the production of activating agents, like RANKL (receptor activator of nuclear factor kappa-B ligand) and M-CSF (macrophage-colony stimulating factor) by mature osteoblasts, which subsequently stimulate the differentiation of osteoclast precursors and hematopoietic progenitor cells to mature osteoclasts, and their activation. Osteoclastogenesis, results in bone resorption and subsequent release of Ca and P into the extracellular fluid. This process is counter forced by the production of agents like osteoprotegerin (OPG) that binds RANKL in order to preclude its osteoclastogenetic effect. The expression of OPG gene is also under the control of 1,25(OH)\(_2\)D\(_3\)-VDR-RXR heterodimer, which downregulates its expression.

### 2.4. Inherited Diseases Associated with Defective Extracellular Ca Sensing Mechanism

CaSR gene is located in chromosome 3q13.3–21, includes 7 exons and encodes for a 1078 amino acids sequence [44]. Loss of function mutations “reset” the serum Ca\(^{2+}\) concentration upward, which leads to calcium-sensing mechanisms stimulation at higher levels of serum Ca\(^{2+}\) than in normal situations, a condition known as Familial Hypocalciuric Hypercalcemia (FHH). A similar biochemical profile is presented in patients with alterations in the downstream signalling proteins Ga\(_i\) and the adaptor-related protein complex 2 (AP2r) which is involved in CaSR endocytosis [45,46]. Heterozygous activating mutations result in increased sensitivity of the receptor to extracellular Ca\(^{2+}\) concentration and induce the reverse effects (Autosomal Dominant Hypocalcaemia, ADH) [47].
2.4.1. Familial Hypocalciuric Hypercalcaemia

Familial Hypocalciuric Hypercalcaemia (FHH) is a rare autosomal -mainly- dominant group of hypercalciemic disorders including 3 subtypes: FHH1, FHH2 and FHH3. Patients exhibit lifelong hypercalcaemia, usually asymptomatic (~70%), with very low urinary Ca\(^{2+}\) excretion (urine Ca:Creatinine clearance ratio <0.01), slightly elevated Mg\(^{2+}\) and often normal concentrations of vitamin D metabolites [45]. PTH circulating levels are mildly elevated which may lead to misdiagnosis of primary hyperparathyroidism (PHPT), since reliable distinctions are not always possible on clinical grounds. The condition is considered to be benign, however, if untreated may lead to severe symptomatic hypercalcaemia, chondrocalcinosis, or nephrocalcinosis (7%), osteomalacia (~9%), gallstones and acute pancreatitis (5.5%). However, in almost 30% of FHH patients, clinical presentation can be atypical [47,48]. It is important to identify these patients to ensure that they are not subjected to parathyroidectomy, which will not correct hypercalcemia [49]. Urine ratio of Ca to creatinine (Ca:Cr) is proposed as a simple biochemical differentiat test. However, ~20% of FHH patient are not hypocaliuric and similarly ~10% of PHPT patients may display a low Ca:Cr ratio [50,51]. Additionally, vitamin D deficiency or impairment of renal function can interfere with Ca\(^{2+}\) renal excretion [52]. Therefore, mutational analysis of FHH causative genes and functional studies of derived variants is the gold standard for a proper diagnosis [53,54].

FHH-1 (MIM 145980) is the most common type accounting for approximately 65% of FHH cases and it is caused by mutations in the CaSR gene. Over 300 mutations have been identified in FHH-1 patients, the majority being missense and the rest harboring frameshift, insertions/deletions and nonsense mutations [47]. Notably, the considerably abnormal transcripts derived by such mutations are not always associated with the severity of clinical phenotype. Therefore, possible mechanisms of inactivating CaSR mutations include: impaired biosynthesis, folding and cellular protein trafficking leading to decreased cell-surface expression [55]; conformational changes and altered G-protein coupling [11] biased signalling responses switched from intracellular Ca\(^{2+}\) pathway to equally or mainly to MAPK reduction [56].

Germline heterozygous inactivating mutations of GNA11 gene, located on 19p13.3 chromosome, are considered the genetic cause of FHH-2 (MIM 14598) [57,58]. The gene encodes for the \(\alpha\)-subunit of G\(_1\) protein, a component of CaSR transduction signalling. To date, 4 probands have been reported carrying 3 different missense substitutions (Thr54Met, Phe220Ser and Leu135Gln) and one an in-frame deletion (Ile200del). FHH-2 patients exhibit a mild clinical phenotype [57,59]. In contrast, FHH-3 (MIM 600740) represents a more severe type with higher degree of hypercalcemia and hypermagnesemia. In some patients, symptomatic hypercalcaemia has been reported, complicated with decreased bone mineral density, cognitive impairment and recurrent pancreatitis. The molecular defect has been identified in AP2S1 (19q13.3), which encodes the AP2\(\sigma\)-subunit [60]. To date, over 60 patients have been reported and all, except from one, carried mutations affecting the Arg15 residue of the protein [47].

The identification of CaSR gene as a causative gene of hypercalciemic disorders, as well as experimental and functional studies provide evidence of a CaSR-mutation dosage effect on clinical phenotype [47,61]. Despite the fact that FHH-1 is an autosomal predominantly dominant disorder there is a small number of patients, the offspring of consanguineous marriages, harboring homozygous CaSR mutations. These individuals display higher values of serum Ca\(^{2+}\) compared to heterozygous patients while their parents were normocalcemic [47]. Functional studies revealed that these mutations had a less severe effect on the receptor compared to mutations with a dominant negative effect [62].

Neonatal severe primary hyperparathyroidism (NSPHT) (MIM 239200) is a rare disorder that presents at birth or within the first six months of life and is characterized by severe life-threatening hypercalcaemia, hypermagnesemia, increased circulating PTH levels, massive hyperplasia of the parathyroid glands and relative hypocalciuria. Mainly homozygous or compound homozygous inactivating mutations in CaSR gene have been
reported while ~15% of the fifty described NSHPT probands were heterozygotes [47]. Half of the 29 NSHPT mutations are missense, located mainly in the N-terminal domain of the protein. Homozygous mutations seem to affect or interrupt CaSR signalling, impair receptor structural integrity and decreased cell-surface expression. Heterozygous mutations are located in key regions for receptor activation [8,12,63]. Serum Ca²⁺ concentrations are higher in homozygous patients compared to heterozygous, while truncated mutants seem to cause increased serum Ca levels compared to missense mutations [47]. Skeletal abnormalities including demineralization, widening of the metaphyses, osteitis fibrosa and fractures may occur. Respiratory distress, failure to thrive, lethargy and dehydration are also commonly observed. In contrast to FHH, hyperplastic parathyroid, obligatory development of permanent hypoparathyroidism and high mortality rate are typically found in NSHPT, thus, total parathyroidectomy is a routine therapy option for NSHPT, following bisphosphonates to limit serum Ca before surgery [63,64].

CaSR has also been demonstrated to be a therapeutic target. Thus, cinacalcet, a positive allosteric modulator of CaSR, has entered clinical practice to treat hyperparathyroid states. Cinacalcet enhances the receptor’s sensitivity to Ca and has been proved to be an effective treatment to some NSHPT patients [65]. Of note, cinacalcet may be used as initial NSHPT treatment due to its impact both on PTH and Ca²⁺ levels [66]. FHH patients usually require no treatment, yet cinacalcet can be efficient in some symptomatic individuals [59].

2.4.2. Autosomal Dominant Hypocalcaemia

Autosomal Dominant Hypocalcaemia (ADH) is a rare familial or sporadic syndrome designated as ADH type 1 (MIM 601198) and type 2 (MIM 615361), caused by activating mutations of CaSR, or GNA11, respectively. The biochemical phenotype, except from additionally short stature in few ADH2 patients, is rather replicated for both types and opposite to FHH [58,67–69]. Hence, ADH is characterised by hypocalcaemia, varying from mild asymptomatic to severe in about half of ADH patients and improper low or normal PTH levels. Low concentrations of PTH, which normally induce reabsorption of Ca²⁺ from the primary filtrate, result in relative hypercalciauria, which is characterized by urinary Ca:Cr ratios that are within or above the reference range. Associated complications include renal stones, nephrocalcinosis, renal impairment and basal calcifications [68]. Symptomatic patients may present with seizures in the neonatal period or later with hypocalcemic manifestations, mainly due to neuromuscular irritability, such as paresthesia, carpopedal spasm or afebrile seizures. Associated complications include renal stones, nephrocalcinosis, renal impairment and basal ganglia calcifications. Affected patients also exhibit hyperphosphatemia, hypomagnesemia and absolute or relative hypercalciauria [68,70]. The impact of such mutations on bone metabolism has not been clarified. ADH1 patients with different gain-of-function CaSR mutations have been reported to exhibit low, normal or even high bone mineral density (BMD) [71]. Occasionally, ADH1 patients may also develop Bartter’s syndrome type V (MIM 601198), and thus, presenting additional features, such as hypokalemia, metabolic alkalosis and hyperaldosteronemia [72].

Approximately 100 different activating CaSR mutations have been reported, the vast majority of which are heterozygous missense substitutions. Genetic alterations seem to locate within specific hotspot sites of the CaSR protein. In particular, ADH1-causing CaSR mutations either affect the extracellular VFT domain, promoting dimer rotation that facilitates receptor activation, [73] or alter specific transmembrane domains and the intervening third extracellular loop of the CaSR, unlocking the protein from its inactive conformation [74]. In contrast to FHH-1, CaSR mutations mentioned previously, ADH1-causing CaSR mutations switch signalling responses from MAPK reduction to intracellular Ca²⁺ pathway [75]. However, twelve CaSR protein residues have been identified to accommodate both ADH1 and FHH mutations, often representing residues which modulate recep-
tor activation and are subject to extended conformational alterations as a response to ligand binding [76]. Pertaining to ADH2, germline activating mutations in GNA11 seem to be very rare and mainly affecting GDP/GTP exchange or G-protein binding [77,78].

Differential diagnosis of ADH from other forms of hypoparathyroidism is of high importance as vitamin D administration may deteriorate hypercalciuria and nephrocalcinosis [68,70]. Generally, therapy of asymptomatic patients is avoided. Whereas, symptomatic disease is encountered either via thiazide diuretics [79] or recombinant human PTH. Calcilytics, negative allosteric CaSR modulators, are a promising option currently in clinical trials. [79]. Murine experimental studies have demonstrated normalization of calcium responses, increased calcium and PTH concentrations and decreased renal calcium loss [80]. This blockage of renal CaSR could also have a role in other hypoparathyroid patients.

2.5. Inherited Diseases Associated with Defective PTH Synthesis and Action

2.5.1. Familial Isolated Hypoparathyroidism, Type 1

In some rare cases of autosomal dominant or recessive hypoparathyroidism, namely Familial Isolated Hypoparathyroidism, type 1 (FIH) (MIM 146200) patients present by heterozygous, homozygous, or compound heterozygous mutation in the PTH gene (11p15.3-p15.1) coding for the prepro-PTH peptide. This region is critical for the movement of the newly formed prepro-PTH through the endoplasmic reticulum and consequently for the full activity of PTH [81]. Patients present hypoparathyroidism, decreased serum Ca²⁺ levels, increased serum levels of Pi and increased Ca²⁺ elimination in the urine. Serum concentrations of PTH are low or undetectable and circulating levels of 1,25(OH)₂D₃ are usually low or low-normal. The clinical symptoms of hypoparathyroidism are synonymous with hypocalcaemia and may vary from quite mild to more severe muscle cramps and convulsions. FIH is also a feature common to a variety of hereditary syndromes, such as ADH type 1 and 2 (described above), or Familial Isolated Hypoparathyroidism-2 (MIM 618883) due to homozygous mutations in “glial cells missing transcription factor-2” gene (GCM2) [82,83]. However, it should be noted that the most common cause of hypoparathyroidism is the loss of parathyroid tissue after surgical removal of the parathyroid glands. Autoimmunity, isolated or associated with other endocrine diseases (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, APECED) and developmental disorders of the parathyroid glands (i.e., DiGeorge syndrome, Charge syndrome, Hypoparathyroidism deafness and renal dysplasia (HDR), Kenny-Caffey syndrome, Kearns-Sayre) may also be causes of hypoparathyroidism [84].

2.5.2. Jansen Metaphyseal Chondrodysplasia

Activating mutations in residues His223 and Thr410 of the PTH1 (3p21.31) have been associated with Jansen metaphyseal chondrodysplasia (MIM156400). It is a rare autosomal form of short-limbed dwarfism, in which neonates appear normal but have radiographic and laboratory abnormalities [85]. They present with metaphyseal chondrodysplasia, hypercalcaemia, hypophosphatemia, undetectable serum levels of PTH and PTHrP, decreased renal tubular reabsorption of P and increased cAMP in urine. Other laboratory findings reveal high level of 1,25(OH)₂D₃, ALP level and urine hydroxyproline. PTH1 ligand analogues, such as DTrp12-PTH(7–34), function as inverse agonists, which can inhibit constitutively active receptors, and thus, could prevent homeostatic abnormalities occurring in these patients [20].

2.5.3. Pseudohypoparathyroidism

PTH, as well as other peptide hormones i.e thyroid stimulating hormone (TSH), use the α subunit of stimulatory guanine-nucleotide binding protein encoded by GNAS gene (20q13.2–13.3) to enhance cAMP production via adenylyl cyclase signalling [86]. Heterozygous mutations in GNAS gene lead to the production of inactive Gαs or to small
amounts of active Gαs, while homozygous deficiency of Gαs is incompatible with life. In this group of disorders, PTH is correctly synthesized, secreted and bound to a well-functioned receptor. However, its binding does not transduce any signal downstream, a condition known as pseudohypoparathyroidism (PHP) [87].

PTH resistance—basically on the proximal renal tubules—is the hallmark of PHP. Patients with PHP present with hypocalcaemia, hyperphosphataemia, diminished serum concentration of 1,25(OH)D3, and increased serum PTH concentration [87,88]. Today, several PHP variants have been identified: PHP type I (1a, 1b, 1c), pseudopseudohypoparathyroidism (PPHP) and PHP type II [88]. In PHP-I types, administration of exogenous biologically active PTH fails to generate, either a hyperphosphaturic or increased cAMP excretion. Whereas, in the PHP-II type, patients have normal cAMP and impaired phosphaturic excretion.

All PHP-Ia (MIM 103580) patients possess heterozygous mutations for GNAS gene resulting in diminished or no cAMP generation. In these patients, there is a markedly attenuated urinary cAMP response (~50%) to exogenous administration of PTH. Furthermore, patients with PHP-Ia present with developmental and somatic defects as a whole are referred to as Albright’s Hereditary Osteodystrophy (AHO) [88,89]. Short stature, round face, brachydactyly, obesity, subcutaneous calcifications and cognitive abnormalities are classic features of AHO. Albright and colleagues, noticed that some patients with the above combination of symptoms had normal Ca, P and PTH serum levels. This variant phenotype is termed PPHP and results from the same mutations in GNAS, which lead to AHO phenotype without PTH resistance [89]. The variation of the aspects of the phenotype depends on the parental origin of the mutation reflecting its imprinted expression [90]. Patients who inherit the defective gene from the father have PPHP (MIM 612463), whereas those who inherit the same mutation from the mother have PHP Ia. For instance, in renal proximal tubules, Gas expression from the paternal allele is silenced, and transcription takes place from the maternal allele. When an inactivating mutation is inherited from a female carrier, the level of Gas in this tissue are affected and hormone resistance occurs (PHP1a). If the defective allele is transmitted from the male carrier, the expression of Gas remains unaltered. However, other dysfunctions of those patients occur after maternal and paternal transmission, indicating haploinsufficiency of Gαs [91].

Patients with PHP type 1b (MIM 603233) lack AHO features and manifest isolated renal resistance to PTH and sometimes mild TSH resistance. Most cases are sporadic, but some cases (10–15%) are familial and show an autosomal dominant mode of inheritance. In familial cases, PTH resistance develops after maternal transmission of the genetic defect, as is the case of PHP1a. Most patients with PHP1b show abnormal patterns of methylation in the differentially methylated regions (DMRs) associated with the GNAS complex locus (20q13) [92–94]. GNAS shows differential methylation at four distinct DMRs: one paternally methylated-DMR (GNAS-NESP: TSS-DMR) and three maternally methylated-DMRs (GNAS-A51:TSS-DMR, GNAS-XL:Ex1-DMR and (GNAS A/B:TSS-DMR) [87]. Familial cases, present usually loss of methylation at GNAS A/B:TSS-DMR, secondary to a 3 kb microdeletion on the maternal allele of cis-acting control elements within STX16 [94]. In nearly all sporadic cases of PHP1B, two or more DMRs, in addition to GNAS A/B:TSS-DMR, are also affected [93]. The severity of PHP type 1b can vary considerably from one patient to another even within single kindred. Members of the affected family who share the same haplotype have been reported to be clinically asymptomatic with normal Ca levels.

PHP type II is a clinically heterogenous syndrome. Only a few cases have been reported and the molecular defect remains elusive. Patients with PHP type II present with hypocalcaemia, decreased serum 1,25(OH)D3, reduced or absent phosphaturic response to exogenous PTH, and a normal increase in urinary cAMP excretion [95].
2.6. Inherited Disorders Associated with Defective Vitamin D Metabolism

2.6.1. Vitamin D Hydroxylation Deficient Rickets, Type 1A, or Pseudovitamin D Deficiency Rickets, or 1α-Hydroxylase Deficiency

Vitamin D Hydroxylation Deficient Rickets, Type 1A (VDDR1A) (MIM 264700) is a rare autosomal recessive disease caused by mutations in CYP27B1 which result in diminished or complete absence of 1α-hydroxylase activity [96]. The biochemical findings are hypocalcaemia, hypophosphatemia, elevated PTH levels due to secondary hyperparathyroidism, increased ALP activity and low urinary Ca\(^{2+}\) excretion. Patients have normal or elevated 25(OH)D levels, but low or undetectable levels of 1,25(OH)\(_2\)D\(_3\). The disorder usually manifests in early life with growth retardation, bone and joint deformities, teeth hypoplasia, hypotonia and muscle weakness. Severe hypocalcaemia can result in seizures and tetany. X-rays reveal classical features of rickets. The low serum levels of 1,25(OH)\(_2\)D\(_3\) and the therapeutic response to physiological doses of exogenous 1,25(OH)\(_2\)D\(_3\) distinguishes 1α-hydroxylase deficiency from Vitamin D-dependent rickets type 2A discussed below [97].

2.6.2. Vitamin D-Dependent Rickets Type 2A

Vitamin D-Dependent Rickets Type 2A (VDDR2A) (MIM 277440) is a rare, clinical entity caused by loss-of-function mutations in the VDR gene, resulting in generalized resistance of target tissues to 1,25(OH)\(_2\)D\(_3\) [37,96–98]. The human VDR is the product of a single chromosomal gene located on chromosome 12 at 12q13–14. It contains 10 exons that code for DNA binding (DBD), hormone binding (LBD) and heterodimerization domains. Mutations in the DBD are associated with complete hormone unresponsiveness whereas the mutations found in the LBD results in heterogeneous degree of resistance to 1,25(OH)\(_2\)D\(_3\) [37]. The disorder follows an autosomal recessive pattern of inheritance and presents with severe rickets, growth retardation, teeth hypoplasia, typical bone deformities like bowed legs and rachitic rosary and occasionally, alopecia. Alopecia can be present at birth or can develop later, during the first year of life. The exact pathophysiologic mechanism causing alopecia is not well-understood. Numerous studies have shown that alopecia is not correlated with Ca\(^{2+}\) or Vitamin D levels, but is associated with the dysfunctional receptor, supporting the role of the receptor in several metabolic pathways. It has been proposed that mutations, affecting DNA binding or RXR heterodimerization cause alopecia, while mutations that prevent the binding of 1,25(OH)\(_2\)D\(_3\) or coactivators to the receptor are not associated with alopecia [98–100]. The biochemical findings include hypocalcaemia, hypophosphatemia, secondary hyperparathyroidism and elevated levels of serum 1,25(OH)\(_2\)D\(_3\) and ALP.

Intravenous calcium administration, followed by high doses of oral calcium is a successful method of treatment of VDDR2A [98]. In some cases, 1,25(OH)\(_2\)D\(_3\) and vitamin D analogues are used [97]. Recently, cinacalcet has been demonstrated to be effective in normalizing hypophosphatemia and the hyperparathyroidism and ameliorate the bone pathology in some patients [101,102]. Spontaneous healing during adolescence has also been described [103]. The desirable laboratory findings after successful treatment are restoration of Ca\(^{2+}\) and Pi to normal levels as well as the decrease in PTH and ALP levels. P levels usually normalize after treatment with Ca, suggesting that hypophosphatemia is mostly associated with the secondary hyperparathyroidism.

3. Phosphorus and Its Partners

Phosphorus (P) is an essential mineral for many biological processes including bone development and metabolism, cell signaling, and muscle contraction. It is also indispensable for cellular structures, nucleic acids, lipids and proteins. Daily P uptake varies between 800–1500 mg, depending of diet. About 65% of this quantity is absorbed in duodenum and jejunum via a paracellular and an active transcellular process through the so-
dium phosphate cotransporter 2b (NaPi-2b), which is controlled by 1,25(OH)₂D₃ and dietary P itself [104]. The skeleton is the main site of P storage in the human body (80–85% of total P), while approximately 15% of the mineral is distributed in extraskeletal sites. In extracellular fluid (1% of total P), it is in the form of inorganic phosphate (Pi). The normal serum Pi concentration ranges from 3.4 to 4.5 mg/dL (1.12 to 1.45 mmol/L). In children, varies from 4 to 7 mg/dL with higher values in neonatal period due to renal immaturity. Renal function is fundamental to Pi serum handling as most of it, is filtered at the glomerulus (about 7 gr daily); 80–90% is reabsorbed by renal tubules (75% in proximal and 10% in distal tubule) and the remainder (~700 mg) is lost in urine, a quantity equal to intestinal absorption. The reabsorption takes place via two transporters on the apical membrane of the proximal tubule, NaPi-2a and NaPi-2c [105,106] regulated by PTH and FGF23 [107].

Although Ca homeostasis has been extensively elucidated, Pi homeostasis is less well understood. PTH, 1,25(OH)₂D₃, and FGF23 are the main regulators of bone, renal and intestinal Pi handling. Recently, it has been shown that hyperphosphatemia inhibits the CaSR in a noncompetitive manner and thus stimulates PTH secretion [108] which in turn increases renal excretion of Pi. Circulating PTH acts through its receptor PTHR1 at the target organs, as described previously for Ca²⁺ homeostasis. Moreover, PTH causes a differential decrease in the abundance of the cotransporters NaPi-2a and NaPi-2c, via a PTH-induced internalization with the synergy of a myosin motor [107]. All molecular mechanisms associated with PTH end by decreasing serum Pi concentration. On the other hand, hypophosphatemia and low serum PTH levels induce 1-α-hydroxylation in the kidney, increasing 1,25(OH)₂D₃ synthesis, which subsequently increases Pi intestinal absorption [109] and renal Pi reabsorption, as described previously.

FGF23 seems to hold a central role in the bone-kidney axis [110]. It is synthesized mainly by osteocytes and to a lesser extent by osteoblasts and acts mainly in kidneys and parathyroid glands as a phosphaturic factor, inhibitor of 1,25(OH)₂D₃ and modulator of PTH synthesis and secretion [111]. 1,25(OH)₂D₃ and extracellular Pi levels enhance FGF23 transcription [112–114]. In the context of a negative feedback loop, FGF23 downregulates 1,25(OH)₂D₃ by both inhibiting 1α-hydroxylase and stimulating 25-hydroxyvitamin D-24-hydroxylase in the kidney. Moreover, FGF23 suppresses the expression of NaPi-2a and NaPi-2c cotransporters on the apical membrane of proximal tubules. As a result, it decreases renal Pi reabsorption [115,116]. FGF23 excess leads to several hypophosphatemic diseases featured by renal Pi wasting and rickets/osteomalacia, while deficient actions of FGF23 result in hyperphosphatemic tumoral calcinosis with enhanced renal Pi reabsorption.

FGF23 actions in the tissues are mediated by FGF receptors (FGFRs), mainly types 1, 3 and 4. Notably, some studies have demonstrated that FGFRs are also significant for FGF23 synthesis [117,118]. FGFR1 is the main receptor via which the FGF23 exerts its renal phosphaturic effect [115]. Following the observation that FGFRs binds with low affinity to FGF23 [119], in vivo and in vitro studies revealed a single pass transmembrane protein, named αKlotho, as an obligate co-receptor. αKlotho has been demonstrated to form a complex, mainly with FGFR1, enhancing receptor’s FGF23-mediated activation [120–122]. Experimental studies on genetic modified mice suggest a collaboration between FGF23 and αKlotho to modulate mineral homeostasis, mostly via their renal effect [120,123]. Therefore, in the kidneys, Klotho mediates the hypophosphatemic action of FGF23 and the downregulation of calcitriol, while in the parathyroid glands it modulates PTH expression [124].

3.1. Hypophosphatemic Rickets with Normal or Decreased FGF23 Levels
3.1.1. Hereditary Hypophosphatemic Rickets with Hypercalciuria
Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) (MIM 241530) is an autosomal recessive disorder with a likely underestimated incidence of 1:250,000, firstly described in a consanguineous kindred [125,126]. Later, inactivating, either homozygous
or compound heterozygous, mutations in the SLC34A3 gene have been identified as the genetic cause of the disorder [127,128]. SLC34A3 is located in chromosome 9q34.3 which encodes the renal sodium-phosphate cotransporter (NaPi-2c). Approximately 40 mutations affecting more than 35 kindreds have been described [129,130]. Deletions (228delC, 905delC) predicting a prematurely terminated translation product and missense mutations (R353L, A413E, G196R, R468W), are most commonly reported [127,128,131]. Generally, impaired function of Na-P cotransporter results in P wasting and hypophosphatemic rickets, short stature, bowing, normal or reduced FGF23 levels, hypercalciuria, elevated 1,25(OH)2D3 and low PTH levels [129,132]. Elevated 1,25(OH)2D3 promotes intestinal Ca absorption leading to hypercalcaemia [129,133] and helps distinguish this disorder from other types of phosphaturic rickets. Furthermore, decreased PTH-dependent Ca-reabsorption in the distal renal tubules contributes to increased renal Ca2+, which along with Pi excretion, results in the development of nephrolithiasis in almost half of HHRH patients. Treatment consists of P administration in order to improve bone mineralization and reduce 1,25(OH)2D3 levels. Therapy with vitamin D analogues is contra-
dicted, as it enhances hypercalcemia and hypercalciuria [129].

3.2. Hypophosphatemic Rickets with Elevated FGF23 Levels

3.2.1. X-linked Hypophosphatemic Rickets (XLH)

XLH rickets (MIM 307800) is inherited with X-linked dominant pattern and consists the most common form of hereditary rickets with an incidence of 1:20,000 [134]. Loss-of-function mutations in PHEX gene have been identified as its causative genetic defect. PHEX (Phosphate regulating with Homologies to Endopeptidases on the X-chromosome), gene is located in chromosome Xp22.1 and is highly expressed in skeleton [135,136]. More than 300 distinct pathogenic variations have been reported [116], leading to FGF23 excess, hypophosphatemia and phosphaturia and inappropriately low levels of 1,25(OH)2D3.

Patients usually exhibit rickets, short stature, growth retardation, bowing of the lower extremities and during adulthood osteomalacia, dental abscesses ectopic calcification, mineralizing enthesopathy and osteoarthropathy [116,135]. Conventional therapy includes multiple doses of oral P supplementation and active vitamin D (calcitriol, alfacalcidol, paricalcitol, eldecalcitol), in order to increase intestinal Pi reabsorption. This therapy can be complicated by hypercalciuria, nephrocalcinosis and secondary hyperparathyroidism. Thiazide diuretics have been used to reduce the risk of nephrocalcinosis, while the calcimimetic drug cinacalcet has been suggested in patients who have developed secondary or tertiary hyperparathyroidism [137,138]. In 2018, burosumab (Crysvita®; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc., Novato, CA, USA), a human neutralizing antibody for FGF23 was approved for the treatment of XLH in adults and children older than 1 year and in 2020 for the treatment of tumor induced osteomalacia [139,140]. Burosumab outweighs conventional therapy in children with XLH pertaining to rickets severity, growth and biochemistries [141].

3.2.2. Autosomal Dominant Hypophosphatemic Rickets

Autosomal Dominant Hypophosphatemic Rickets (ADHR) (MIM 193100) is a rare disorder that follows autosomal dominant inheritance with incomplete penetrance. FGF23 gene is located in chromosome 12p13.3, encompassing 3 exons and the derived protein consists of 251 amino acids including a signal peptide of 24 aa in the N-terminal. Under physiological circumstances, FGF23 is present in serum in the active form of an intact peptide (25th to 251th aa). FGF inactive fragments are derived after proteolytic processing by endopeptidases that recognize a specific subtilisin-like proprotein convertase (SPC) cleavage site R228XXR229 [142]. Activating mutations in this site are the causative genetic defect of ADHR, while inactivating mutations result in hyperphosphatemia and elevated 1,25(OH)2D3 levels [143]. Increased FGF23 activity results in suppressed co-transporters
Genes 2021, 12, 734

NaPi-2a and NaPi-2c, as well as in decreased 1a hydroxylase expression and hypophosphatemia [143].

Clinical manifestations and biochemical findings resemble XLH. However, affected patients may present with a variable phenotype. Patients with a childhood onset may develop severe rickets accompanied by short stature and bone deformities. While others may appear with delayed onset of the disease in adolescence or adulthood and milder symptoms, like muscle weakness and bone pain, without limb deformities [144,145]. FGF23 levels have been reported to correlate with the disease’s severity. Spontaneous normalization of serum P levels has also been reported [146]. Converging data suggest that the clinical phenotype of ADHR is temporally associated to the existence of iron deficiency, as iron status seems to influence FGF23 concentrations [144,147]. ADHR therapeutic options are similar to XLH conventional therapy along with recognition and treatment of iron deficit [148]. Although burosumab is a promising regimen for the remainder of FGF23-mediated disorders, its efficiency has to be proved in clinical trials [149].

3.2.3. Diseases Associated with FGFR1 gene Mutations

Osteoglophonic Dysplasia (MIM66250), a very rare type of dwarfism, is caused by gain of function mutations of FGFR1. Hypophosphatemia and low 1,25(OH)2D3 levels accompanied by chondrodysplasia, craniosynostosis and spondyloepiphyseal dysplasia in imaging studies are disease’s characteristic manifestations [150]. Mutations in this receptor have been also associated with a spectrum of phenotypically different rare syndromes such as Pfeiffer, Kallmann, Trigonocephaly, Jackson–Weiss and Hartsfield [151].

3.2.4. Autosomal Recessive Hypophosphatemic Rickets

Autosomal Recessive Hypophosphatemic Rickets (ARHR) type 1 (MIM 241520) and 2 (MIM 613312) are associated with molecular defects in Dentin matrix protein 1 (DMP1) and the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), respectively [152,153]. DMP1 is located in chromosome 4q21.1 and 13 distinct mutations have been reported in 32 patients of 16 families. DMP1 belongs to the SIBLING (Small Integrin Binding Ligand N-linked Glycoprotein) protein family, a group of non-collagenous extracellular matrix proteins and is expressed in osteoblasts and osteocytes, promoting proper growth and formation of hydroxyapatite crystals [154]. DMP1 is cleaved into two fragments of 35 and 57 kDa. The C-terminal fragment of 57 kDa appears to suppress FGF23 expression [155], while patients harboring mutations that affect the DMP1 fragment present with shorter stature and lower serum Pi level, compared to those harboring mutations only affecting N-terminal fragment of the protein [156]. Overall, clinical findings of ARHR patients are similar to those appearing in other types of hypophosphatemic rickets. Interestingly, there are some hypophosphatemic patients, carriers of a DMP1 mutation, who present with increased bone density and overgrowth of tubular bones [156].

ENPP1, located in chromosome 6q22.23, encodes for a plasma protein which controls the generation of inorganic pyrophosphate (Pi), which inhibit hydroxyapatite crystal deposition by hydrolyzation of ATP to AMP [157]. ENPP1 has also been identified as the causative gene of another entity, generalized arterial calcification in infancy (GACII), presenting precociously with arterial calcification [158]. However, patients with ARHR do not develop GACI, probably due to low P levels [153]. Clinical features resemble other types of hypophosphatemic rickets, while primary hyperparathyroidism has been also described in a recent report [159].

Mutations in FAMC20 gene have been recently associated with a nonlethal variant of Raine syndrome as a novel form of FGF23-related hypophosphatemia and hyperphosphaturia and proposed to represent a third form of ARHR [160,161]. FAMC20 is a Golgi kinase supported to be involved in the post-translational modification of FGF23. FAMC20 phosphorylates FGF23 and promotes its cleavage, while a recent report suggests the SIBLING-proteins to be substrates for FAM20C. Clinically additional finding include severe dental anomalies, osteosclerosis, intracerebral calcifications and dysmorphic features [160].
Treatment of ARHR is similar to the conventional treatment of the other hypophosphatemic disorders already discussed above.

3.2.5. Diseases Associated with Klotho Gene Mutations

The genetic evaluation of a patient with hypophosphatemic rickets and increased plasma soluble Klotho, revealed a translocation between chromosome 9 and 13, with a breakpoint in vicinity to Klotho (KL) gene. Besides elevated Klotho levels, patients displayed increased enzymatic activity protein and FGF23 concentrations accompanied by clinical and biochemical findings of hypophosphatemic rickets [162]. Interestingly, the patient presented with parathyroid hyperplasia and markedly elevated PTH levels. The underlying mechanism of this manifestation remains elusive.

On the other hand, Familiar Tumor Calcinosis (FTC), a rare autosomal recessive disorder, is a mirror image of FGF23 related hypophosphatemic diseases, featured by hyperphosphatemia, inappropriately elevated 1,25(OH)2D3 and PTH levels and ectopic calcified masses, [163]. The genetic defect of the disorder is loss-of-function mutations either in KL gene or FGF23 or N-acetyl-galactosaminyltransferase (GALNT3)—an enzyme involving in FGF23 O-glycosylation. In KL gene, only one a missense mutation has been reported in a single FTC patient [131].

4. Conclusions

Inherited disorders affecting Calcium and Phosphorus metabolism are mainly rare diseases, often with overlapping clinical and biochemical features, thus, making their diagnosis challenging. In this review, we aim to connect the known molecular alterations affecting the actors of Ca/P signalling, their effects on the molecules downstream, and their impact on the biochemical profile of the patients. The knowledge of the genetic basis helps in understanding the biology and the aetiopathogenesis of the diseases and therefore ensures more accurate diagnosis and therapeutic approach. The study of the CaSR and the Ca sensing mechanisms resulted in new therapeutic options—calcimimetics or calcilytics that modulate the activity of the receptor. The identification of the role of FGF23 and PHEX improved the conventional therapy for XLH, since a human neutralizing antibody for FGF23, burosumab, was approved for the treatment of XLH and tumor induced osteomalacia. It seems that there are still unknown interactions in this complex network between bone-kidney-intestine and parathyroid glands that are waiting to be discovered.

Author Contributions: Conceptualization A.P.; Writing—original draft preparation A.P. and E.B., Writing—review and editing A.P., E.B., F.-E.K.; Funding acquisition, F.-E.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: We cordially thank S. Liarou for her precious help in formatting the schematic illustration.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Peacock, M. Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 2010, 5 (Suppl. 1), S23–S30, doi:10.2215/CJN.05910809.

2. Moe, S.M. Calcium Homeostasis in Health and in Kidney Disease. Compr. Physiol. 2016, 6, 1781–1800, doi:10.1002/cphy.c150052.

3. Moore, E.W. Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J. Clin. Invest. 1970, 49, 318–334, doi:10.1172/JCI106241.

4. Gattinoni, J. Inherited disorders of calcium and phosphate metabolism. Curr. Opin. Pediatr. 2014, 26, 215–222, doi:10.1097/MOP.0000000000000064.

5. Goltzman, D.; Mannstadt, M.; Marcocci, C. Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis. Front. Horm. Res. 2018, 50, 1–13, doi:10.1159/000486060.

6. Friedman, P.A.; Gesek, F.A. Cellular calcium transport in renal epithelia: Measurement, mechanisms, and regulation. Physiol. Rev. 1995, 75, 429–471, doi:10.1152/physrev.1995.75.3.429.

7. Hannan, F.M.; Kallay, E.; Chang, W.; Brandt, M.L.; Thakker, R.V. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 2018, 15, 33–51, doi:10.1038/s41574-018-0115-0.

8. Geng, Y.; Mosyak, L.; Kurnov, I.; Žuo, H.; Sturchler, E.; Cheng, T.C.; Subramanyam, P.; Brown, A.P.; Brennan, S.C.; Mun, H.C.; et al. Structural mechanism of ligand activation in human calcium-sensing receptor. eLife 2016, 5, e13662, doi:10.7554/eLife.13662.

9. Hannan, F.M.; Babinsky, V.N.; Thakker, R.V. Disorders of the calcium-sensing receptor and partner proteins: Insights into the molecular basis of calcium homeostasis. J. Mol. Endocrinol. 2016, 57, R27–R142, doi:10.1530/JME-16-0124.

10. Huang, Y.; Zhou, Y.; Yang, W.; Butters, R.; Lee, H.-W.; Li, S.; Castilblanco, A.; Brown, E.M.; Yang, J.J. Identification and Dissection of Ca²⁺-binding Sites in the Extracellular Domain of Ca²⁺-sensing Receptor. J. Biol. Chem. 2007, 282, 19000–19010, doi:10.1074/jbc.M701096200.

11. Conigrave, A.D.; Ward, D.T. Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 315–331, doi:10.1016/j.beem.2013.05.010.

12. Zhang, C.; Zhang, T.; Zou, J.; Miller, C.L.; Gorkhali, R.; Yang, J.Y.; Schlimiller, A.; Wang, S.; Huang, K.; Brown, E.M.; et al. Structural basis for regulation of human calcium-sensing receptor by magnesium ions and an unexpected tryptophan derivative co-agonist. Sci. Adv. 2016, 2, e1600241, doi:10.1126/sciadv.20160241.

13. Conigrave, A.D. The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future. Front. Physiol. 2016, 7, 563, doi:10.3389/fphys.2016.00563.

14. Hjalm, G.; MacLeod, R.J.; Kifor, O.; Chattopadhyay, N.; Brown, E.M. Filamin-A binds to the carboxy-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. J. Biol. Chem. 2001, 276, 34880–34887, doi:10.1074/jbc.M100784200.

15. Kifor, O.; Kifor, I.; Moore, F.D.; Butters, R.R.; Cantor, T.; Gao, P.; Brown, E.M. Decreased Expression of Caveolin-1 and Altered Regulation of Mitogen-Activated Protein Kinase in Cultured Bovine Parathyroid Cells and Human Parathyroid Adenomas. J. Clin. Endocrinol. Metab. 2003, 88, 4455–4464, doi:10.1210/jc.2002-021427.

16. Goodman, W.G.; Veldhuis, J.D.; Belin, T.R.; van Herle, A.J.; Juppner, H.; Salusky, I.B. Calcium-Sensing by Parathyroid Glands in Secondary Hyperparathyroidism.1. J. Clin. Endocrinol. Metab. 1998, 83, 2765–2772, doi:10.1210/jcem.83.8.4999.

17. Gordon, R.J.; Levine, M.A. Genetic Disorders of Parathyroid Development and Function. Endocrinol. Metab. Clin. N. Am. 2018, 47, 809–823, doi:10.1016/j.ecl.2018.07.007.

18. Brown, E.M. Physiology of calcium homeostasis. In The Parathyroids; Bilezikian, J.P., Marcus, R., Levine, A., Ed.; Academic Press: Cambridge, MA, USA, 2001; pp. 167–182.

19. Shaker, J.L.; Deftos, L. Calcium and Phosphate Homeostasis. In Endotext; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dungan, K., Grossman, A., Hershman, J.M., Hofland, J., Kaltas, G., et al., Eds.; MDText.com, Inc: South Dartmouth, MA, USA, 2000.

20. Cheloha, R.W.; Gallman, S.H.; Vilardaga, J.P.; Gardella, T.J. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat. Rev. Endocrinol. 2015, 11, 712–724, doi:10.1038/nrendo.2015.139.

21. Goltzman, D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch. Biochem. Biophys. 2008, 473, 218–224, doi:10.1016/j.abb.2008.03.003.

22. Haddad, J.G. Vitamin D—Solar rays, the Milky Way, or both? N. Engl. J. Med. 1992, 326, 1213–1215, doi:10.1056/NEJM199204303261808.

23. Holick, M.F. Vitamin D: A millenium perspective. J. Cell. Biochem. 2002, 88, 296–307, doi:10.1002/jcb.10338.

24. Hossein-Nezhad, A.; Holick, M.F. Vitamin D for Health: A Global Perspective. Mayo Clin. Proc. 2013, 88, 720–755, doi:10.1016/j.mayocp.2013.05.011.

25. Allgrove, J. Is nutritional rickets returning? Arch. Dis. Child. 2004, 89, 699–701, doi:10.1136/adc.2003.036780.

26. Nicolaïdou, P.; Hatzistamatiou, Z.; Papadopoulou, A.; Kalejias, J.; Floropoulou, E.; Lagona, E.; Tsalgiris, V.; Costalos, C.; Antsaklis, A. Low Vitamin D Status in Mother-Newborn Pairs in Greece. Calcif. Tissue Int. 2006, 78, 337–342, doi:10.1007/s00223-006-0007-5.

27. Papadopoulou, A.; Bountouvi, E.; Papaevaggelou, V.; Priftis, K.N. Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood. Mini Rev. Med. Chem. 2015, 15, 900–912, doi:10.2174/13895575166615051905741.
28. Zhu, J.G.; Ochalek, J.T.; Kaufmann, M.; Jones, G.; DeLuca, H.F. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. *Proc. Natl. Acad. Sci. USA* 2013, 110, 15650–15655, doi:10.1073/pnas.1315006110.

29. Cali, J.J.; Hsieh, C.L.; Francke, U.; Russell, D.W. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. *J. Biol. Chem.* 1991, 266, 7779–7783.

30. Thacher, T.D.; Fischer, P.R.; Singh, R.J.; Roizen, J.; Levine, M.A. CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. *J. Clin. Endocrinol. Metab.* 2015, 100, E1005–E1013, doi:10.1210/jc.2015-1746.

31. Hollick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* 2011, 96, 1911–1930, doi:10.1210/jc.2011-0385.

32. Bikle, D.D. Extra Renal Synthesis of 1,25-dihydroxyvitamin D and its Health Implications. *Clin. Rev. Bone Miner. Metab.* 2009, 7, 114–125.

33. St-Arnaud, R.; Messerlian, S.; Moir, J.M.; Omdahl, J.L.; Glorieux, F.H. The 25-hydroxyvitamin D 1-α-Hydroxylase Gene Maps to the Pseudovitamin D-Deficiency Rickets (PDDR) Disease Locus. *J. Bone Miner. Res.* 1997, 12, 1552–1559, doi:10.1359/jbmr.1997.12.10.1552.

34. Bikle, D. Vitamin D: Production, Metabolism, and Mechanisms of Action. In *Endotext*: Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dungan, K., Grossman, A., Hershman, J.M., Hofland, J., Kaltasas, G., et al., Eds.; MDText.com, Inc: South Dartmouth, MA, USA, 2000.

35. Xie, Z.; Munson, S.J.; Huang, N.; Portale, A.A.; Miller, W.L.; Bikle, D.D. The Mechanism of 1,25-Dihydroxyvitamin D3Autoregulation in Keratinocytes. *J. Biol. Chem.* 2002, 277, 36987–36990, doi:10.1074/jbc.M201404200.

36. Schlingmann, K.P.; Kaufmann, M.; Weber, S.; Irwin, A.; Goos, C.; John, U.; Misselwitz, J.; Klaus, G.; Kuwertz-Bröking, E.; Feehrenbach, H.; et al. Mutations in CYP24A1and Idiopathic Infantile Hypercalcaemia. *N. Engl. J. Med.* 2011, 365, 410–421, doi:10.1056/NEJMoai1103864.

37. Malloy, P.J.; Pike, J.W.; Feldman, D. The Vitamin D Receptor and the Syndrome of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets. *Endocr. Rev.* 1999, 20, 156–188, doi:10.1210/edrv.20.2.0359.

38. Jones, G.; Strugnell, S.A.; DeLuca, H.F. Current understanding of the molecular actions of vitamin D. *Physiol. Rev.* 1998, 78, 1193–1231, doi:10.1152/physrev.1998.78.4.1193.

39. Carlberg, C.; Seuter, S.; Heikkinen, S. The first genome-wide view of vitamin D receptor locations and their mechanistic implications. *Anticancer Res.* 2012, 32, 271–282.

40. Hossein Nezhad, A.; Spira, A.; Holick, M.F. Influence of Vitamin D Status and Vitamin D3 Supplementation on Genome Wide Expression of White Blood Cells: A Randomized Double-Blind Clinical Trial. *PloS ONE* 2013, 8, e58725, doi:10.1371/journal.pone.0058725.

41. Wasserman, R.H.; Kallfelz, F.A.; Comar, C.L. Active transport of calcium by rat duodenum in vivo. *Science* 1961, 133, 883–884.

42. Kumar, R.; Scafer, J.; Grande, J.P.; Roche, P.C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. *Am. J. Physiol.* 1994, 266, F477–F485, doi:10.1152/ajprenal.1994.266.3.F477.

43. Bikle, D.D.; Bouillon, R. Vitamin D and bone and beyond. *Bone Rep.* 2018, 9, 120–121, doi:10.1016/j.bonr.2018.07.003.

44. Garrett, J.E.; Capuno, I.V.; Hammerland, L.G.; Hung, B.C.; Brown, E.M.; Hebert, S.C.; Nemeth, E.F.; Fuller, F. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. *J. Biol. Chem.* 1995, 270, 12919–12925, doi:10.1074/jbc.270.21.12919.

45. Christensen, S.E.; Nissen, P.H.; Vestergaard, P.; Heickendorff, L.; Rejmark, L.; Brixen, K.; Mosekilde, L. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcaemia and primary hyperparathyroidism. *Eur. J. Endocrinol.* 2008, 159, 719–727, doi:10.1530/EJE-08-0440.

46. Gorvin, C.M.; Metpally, R.; Stokes, V.J.; Hannon, F.M.; Krishnamurthy, S.B.; Overton, J.D.; Reid, J.G.; Breitwieser, G.E.; Thakker, R.V. Large-scale exome datasets reveal a new class of adaptor-related protein complex 2 sigma subunit (AP2sigma) mutations, located at the interface with the AP2 alpha subunit, that impair calcium-sensing receptor signalling. *Hum. Mol. Genet.* 2018, 27, 901–911, doi:10.1093/hmg/ddy010.

47. Gorvin, C.M. Molecular and clinical insights from studies of calcium-sensing receptor mutations. *J. Mol. Endocrinol.* 2019, 63, R1–R16, doi:10.1530/JME-19-0104.

48. Pearce, S.H.; Wooding, C.; Davies, M.; Tollefsen, S.E.; Whyte, M.P.; Thakker, R.V. Calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia with recurrent pancreatitis. *Clin. Endocrinol.* 1996, 45, 675–680, doi:10.1046/j.1365-2265.1996.750891.x.

49. Sagi, S.V.; Joshi, H.; Trotman, J.; Elsey, T.; Swamy, A.; Rajkanna, J.; Bhat, N.A.; Haddadin, F.J.S.; Oyibo, S.O.; Park, S.-M. A novel CASR variant in a family with familial hypocalciuric hypercalcaemia and primary hyperparathyroidism. *Endocrinol. Diabetes Metab. Case Rep.* 2020, 2020, doi:10.1530/edm-20-0084.

50. Eastell, R.; Brandi, M.L.; Costa, A.G.; D’Amour, P.; Shoback, D.M.; Thakker, R.V. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. *J. Clin. Endocrinol. Metab.* 2014, 99, 3570–3579, doi:10.1210/jc.2014-1414.

51. Marx, S.J. Letter to the editor: Distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcaemia by using an index of urinary calcium. *J. Clin. Endocrinol. Metab.* 2015, 100, L29–L30, doi:10.1210/jc.2014-2221.
Genes 2021, 12, 734

52. Christensen, S.E.; Nissen, P.H.; Vestergaard, P.; Heickendorff, L.; Brixen, K.; Moskilde, L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: A follow-up study on methods. *Clin. Endocrinol.* 2008, 69, 713–720, doi:10.1111/j.1365-2265.2008.03259.x.

53. Arshad, M.F.; McAllister, J.; Merchant, A.; Rab, E.; Cook, J.; Eastell, R.; Balasubramanian, S. Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): Which test performs best? *Postgrad. Med. J.* 2020, doi:10.1136/postgradmedj-2020-137718.

54. Magno, A.L.; Leatherbarrow, K.M.; Brown, S.J.; Wilson, S.G.; Walsh, J.P.; Ward, B.K. Functional Analysis of Calcium-Sensing Receptor Variants Identified in Families Provisionally Diagnosed with Familial Hypocalciuric Hypercalcaemia. *Calcif. Tissue Int.* 2020, 107, 230–239, doi:10.1007/s00223-020-00715-1.

55. Pidasevsa, S.; Grant, M.; Canaff, L.; Ercan, O.; Kumar, U.; Hendy, G.N. Calcium-sensing receptor dimerizes in the endoplasmic reticulum: Biochemical and biophysical characterization of CASR mutants retained intracellularly. *Hum. Mol. Genet.* 2006, 15, 2200–2209, doi:10.1093/hmg/ddl115.

56. Leach, K.; Wan, A.; Cook, A.E.; Sexton, P.M.; Conigrave, A.D.; Christopoulos, A. Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. *Endocrinology* 2013, 154, 1105–1116, doi:10.1210/en.2012-1887.

57. Gorvin, C.M.; Cranston, T.; Hannan, F.M.; Rust, N.; Qureshi, A.; Nesbit, M.A.; Thakker, R.V. A G-protein Subunit-a11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcaemia Type 2 (FHH2). *J. Bone Miner. Res.* 2016, 31, 1200–1206, doi:10.1002/jbmr.2778.

58. Nesbit, M.A.; Hannan, F.M.; Howes, S.A.; Babinsky, V.N.; Head, R.A.; Cranston, T.; Rust, N.; Hobbs, M.R.; Heath, H.; III; Thakker, R.V. Mutations affecting G-protein subunit alpha11 in hypercalcaemia and hypocalcaemia. *N. Engl. J. Med.* 2013, 368, 2476–2486, doi:10.1056/NEJMoa1300253.

59. Gorvin, C.M.; Hannan, F.M.; Cranston, T.; Valta, H.; Makitie, O.; Schalin-Jantti, C.; Thakker, R.V. Cinacalcet Rectifies Hypercalcaemia in a Patient with Familial Hypocalciuric Hypercalcaemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Galpha11 Mutation. *J. Bone Miner. Res.* 2018, 33, 32–41, doi:10.1002/jbmr.3241.

60. Gorvin, C.M.; Rogers, A.; Hasty, B.; Tarasov, A.I.; Frost, M.; Sposini, S.; Inoue, A.; Whyte, M.P.; Rorsman, P.; Hanyaloglu, A.C., et al. AP2sigma Mutations Impair Calcium-Sensing Receptor Trafficking and Signaling, and Show an Endosomal Pathway to Spatially Direct G-Protein Selectivity. *Cell Rep.* 2018, 22, 1054–1066, doi:10.1016/j.celrep.2017.12.089.

61. Pollak, M.R.; Chou, Y.H.; Marx, S.J.; Steinmann, B.; Cole, D.E.; Brandi, M.L.; Papapoulos, S.E.; Menko, F.H.; Hendy, G.N.; Brown, E.M.; et al. Familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. *J. Clin. Investig.* 1994, 93, 1108–1112, doi:10.1122/JCI117062.

62. Hannan, F.M.; Nesbit, M.A.; Christie, P.T.; Lissens, W.; van der Schueren, B.; Rex, M.; Bouillon, R.; Thakker, R.V. A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is associated with isolated primary hyperparathyroidism: Correlation between location of mutations and severity of hypercalcaemia. *Clin. Endocrinol.* 2010, 73, 715–722, doi:10.1111/j.1365-2265.2010.03870.x.

63. Marx, S.J.; Sinaii, N. Neonatal Severe Hyperparathyroidism: Novel Insights from Calcium, PTH, and the CASR Gene. *J. Clin. Endocrinol. Metab.* 2020, 105, 1061–1078, doi:10.1210/clinem/dgzz23.

64. Lee, J.Y.; Shoback, D.M. Familial hypocalciuric hypercalcaemia and related disorders. *Best Pract. Res. Clin. Endocrinol. Metab.* 2018, 32, 609–619, doi:10.1016/j.beem.2018.05.004.

65. Gannon, A.W.; Monk, H.M.; Levine, M.A. Cinacalcet monotherapy in neonatal severe hyperparathyroidism: A case study and review. *J. Clin. Endocrinol. Metab.* 2014, 99, 7–11, doi:10.1210/jc.2013-2834.

66. Mayr, B.M.; Schnabel, D.; Dörr, H.-G.; Schöfl, C. Genetics in Endocrinology: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. *Eur. J. Endocrinol.* 2016, 174, R189–R208, doi:10.1530/EJE-15-1028.

67. Pearce, S.H.; Williamson, C.; Kifor, O.; Bai, M.; Goulthard, M.G.; Davies, M.; Lewis-Barned, N.; McCredie, D.; Powell, H.; Kendall-Taylor, P., et al. A familial syndrome of hypercalcaemia with hypercalciuria due to mutations in the calcium-sensing receptor. *N. Engl. J. Med.* 1996, 335, 1115–1122, doi:10.1056/NEJM199610103351505.

68. Roszko, K.L.; Bi, R.D.; Mannstadt, M. Autosomal Dominant Hypocalcaemia (Hyperparathyroidism) Types 1 and 2. *Front. Physiol.* 2016, 7, 458, doi:10.3389/fphys.2016.00458.

69. Dershem, R.; Gorvin, C.M.; Metpally, R.P.; Krishnamurthy, S.; Smelser, D.T.; Hannan, F.M.; Carey, D.J.; Thakker, R.V.; Breitwieser, G.E. Familial Hypocalciuric Hypercalcaemia Type 1 and Autosomal-Dominant Hypocalcaemia Type 1: Prevalence in a Large Healthcare Population. *Am. J. Hum. Genet.* 2020, 106, 734–747, doi:10.1016/j.ajhg.2020.04.006.

70. Hannan, F.M.; Thakker, R.V. Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. *Best Pract. Res. Clin. Endocrinol. Metab.* 2013, 27, 359–371, doi:10.1016/j.beem.2013.04.007.

71. Papadopoulou, A.; Cole, E.; Melachrinou, K.; Trangas, T.; Bountouvi, Y.; Papadimitriou, A. Clinical characterization of a novel calcium sensing receptor genetic alteration in a Greek patient with autosomal dominant hypocalcaemia type 1. *Hormones* 2017, 16, 200–204, doi:10.14313/horm.2002.1734.

72. Watanabe, S.; Fukumoto, S.; Chang, H.; Takeuchi, Y.; Hasegawa, Y.; Okazaki, R.; Chikatsu, N.; Fujita, T. Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. *Lancet* 2002, 360, 692–694, doi:10.1016/S0140-6736(02)09842-2.
73. Hu, J.; Spiegel, A.M. Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators. J. Cell. Mol. Med. 2007, 11, 908–922, doi:10.1111/j.1582-4934.2007.00096.x.

74. Dore, A.S.; Okrasa, K.; Patel, J.C.; Serrano-Vega, M.; Bennett, K.; Cooke, R.M.; Errey, J.C.; Jazayeri, A.; Khan, S.; Tehan, B.; et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 2012, 493, 84–92, doi:10.1038/nature11336.

75. Leach, K.; Wen, A.; Davey, A.E.; Sexton, P.M.; Conigrave, A.D.; Christopoulos, A. Identification of molecular phenotypes and biased signaling induced by naturally occurring variations in the human calcium-sensing receptor. Endocrinology 2012, 153, 4304–4316, doi:10.1210/en.2012-1449.

76. Zhang, C.; Mulpuri, N.; Hannan, F.M.; Nesbit, M.A.; Thakker, R.V.; Hamelberg, D.; Brown, E.M.; Yang, J.J. Role of Ca2+ and L-Phe in regulating functional cooperativity of disease-associated “toggle” calcium-sensing receptor mutations. PLoS ONE 2014, 9, e113622, doi:10.1371/journal.pone.0113622.

77. Li, D.; Opas, E.E.; Tuluc, F.; Metzger, D.J.; Hou, C.; Hakonarson, H.; Levine, M.A. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: Phenotypic and molecular characterization. J. Clin. Endocrinol. Metab. 2014, 99, E1774–E1783, doi:10.1210/jc.2014-1029.

78. Piret, S.E.; Gorvin, C.M.; Pagamenta, A.T.; Howles, S.A.; Cranston, T.; Rust, N.; Nesbit, M.A.; Glaser, B.; Taylor, J.C.; Buchs, A.E.; et al. Identification of a G-Protein Subunit-alpha11 Gain-of-Function Mutation, Val340Met, in a Family with Autosomal Dominant Hypocalcemia Type 2 (ADH2). J. Bone Miner. Res. 2016, 31, 1207–1214, doi:10.1002/jbmr.2797.

79. Sato, K.; Hasegawa, Y.; Nakae, J.; Nanao, K.; Takahashi, I.; Tajima, T.; Shinohara, N.; Fujieda, K. Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 2002, 87, 3068–3073, doi:10.1210/jcem.87.7.6839.

80. Dong, B.; Endo, I.; Ohnishi, Y.; Kondo, T.; Hasegawa, T.; Amizuka, N.; Kiyonari, H.; Shioi, G.; Abe, M.; Fukumoto, S.; et al. Calclutidic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH). J. Bone Miner. Res. 2015, 30, 1980–1993, doi:10.1002/jbmr.2551.

81. Cinque, L.; Sparanese, A.; Penta, L.; Mencarelli, A.; Rogaia, D.; Esposito, S.; Fabrizio, F.P.; Baorda, F.; Verrotti, A.; Falomi, A.; et al. Autosomal Dominant PTH Gene Signal Sequence Mutation in a Family with Familial Isolated Hypoparathyroidism. J. Clin. Endocrinol. Metab. 2017, 102, 3961–3969, doi:10.1210/jc.2017-00250.

82. Hendy, G.N.; Cole, D.E.C. Familial isolated hypoparathyroidism. In Hypoparathyroidism; Brandi, M.L., Brown, E., Eds.; Springer-Verlag: Milan, Italy, 2015.

83. García-Castano, A.; Madariaga, L.; Gomez-Conde, S.; Cordo, C.L.R.; Lopez-Iglesias, M.; Garcia-Fernandez, Y.; Martin, A.; Gonzalez, P.; Goicolea, I.; de Nanclares, G.P.; Five patients with disorders of calcium metabolism presented with GCM2 gene variants. Sci. Rep. 2021, 11, 2968, doi:10.1038/s41598-021-82661-y.

84. Hendy, G.N.; Cole, D.E.C.; Bastep, M. Hypoparathyroidism and Pseudohypoparathyroidism. In Endotext; Feingold, K.R., Anawalt, B.; Boyce, A.; Chrousos, G.; de Herder, W.W.; Dungan, K.; Grossman, A.; Hershman, J.M.; Hofland, J.; Kalttsas, G.; et al.; Eds.; MDText.com, Inc, South Dartmouth, MA, USA, 2000.

85. Schipani, E.; Jensen, G.S.; Pincus, J.; Nissenson, R.A.; Gardella, T.J.; Juppner, H. Constitutive activation of the cyclic adenosine 3′,5′-monophosphate sensing pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen’s metaphyseal chondrodysplasia. Mol. Endocrinol. 1997, 11, 851–858, doi:10.1210/mend.11.7.9934.

86. Bastep, M. The GNAS locus and pseudohypoparathyroidism. Adv. Exp. Med. Biol. 2008, 626, 27–40, doi:10.1007/978-0-387-77756-0_3.

87. Mantovani, G.; Bastep, G.; Monk, D.; de Sanctis, L.; Thiele, S.; Usardi, A.; Ahmed, S.F.; Bufo, R.; Chaplin, T.; de Filippo, G.; et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: First international Consensus Statement. Nat. Rev. Endocrinol. 2018, 14, 476–500, doi:10.1038/s41574-018-0042-0.

88. De Nanclares, G.P.; Fernandez-Rebollo, E.; Santin, I.; Garcia-Cuartero, B.; Gaztambide, S.; Menendez, E.; Morales, M.J.; Pombo, M.; Bilbao, J.R.; Barros, F.; et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J. Clin. Endocrinol. Metab. 2007, 92, 2370–2373, doi:10.1210/jc.2006-2287.

89. Albright, F.; Forbes, A.P.; Henneman, P.H. Pseudo-pseudohypoparathyroidism. Trans. Assoc. Am. Physicians 1952, 65, 337–350.

90. Plagge, A.; Kelsey, G.; Germain-Lee, L.I. Physiological functions of the imprinted Gnas locus and its protein variants Galph(s) and XLalph(s) in human and mouse. J. Endocrinol. 2008, 196, 193–214, doi:10.1677/JOE-07-0544.

91. Thiele, S.; de Sanctis, L.; Werner, R.; Grotzinger, J.; Aydin, C.; Juppner, H.; Bastep, M.; Hiort, O. Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type 1c defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsalph(a)-receptor interaction. Hum. Mutat. 2011, 32, 653–660, doi:10.1002/humu.21489.

92. Liu, J.; Litman, D.; Rosenberg, M.J.; Yu, S.; Biesecker, L.G.; Weinstein, L.S. A GNAS1 imprinting defect in pseudohypoparathyroidism type Ib. J. Clin. Invest. 2000, 106, 1167–1174, doi:10.1172/JCI10431.

93. Liu, J.; Nealon, J.G.; Weinstein, L.S. Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type Ib. Hum. Mol. Genet. 2005, 14, 95–102, doi:10.1093/hmg/ddi009.

94. Bastep, M.; Frohlich, L.F.; Hendy, G.N.; Indridason, O.S.; Josse, R.G.; Koshiyama, H.; Korkk, J.; Nakamoto, J.M.; Rosenbloom, A.L.; Slyper, A.H.; et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J. Clin. Invest. 2003, 112, 1255–1263, doi:10.1172/JCI19159.
95. Drezner, M.; Neelon, F.A.; Lebovitz, H.E. Pseudohyoparathyroidism type II: A possible defect in the reception of the cyclic AMP signal. N. Engl. J. Med. 1973, 289, 1056–1060, doi:10.1056/NEJM197311152892003.

96. Miller, W.L. Genetic disorders of Vitamin D biosynthesis and degradation. J. Steroid Biochem. Mol. Biol. 2017, 165, 101–108, doi:10.1016/j.jsbmb.2016.04.001.

97. Nicolaidou, P.; Tsitsika, A.; Papadimitriou, A.; Karantana, A.; Papadopoulou, A.; Psychou, F.; Liakopoulou, D.; Georgouli, H.; Kakourou, T.; Chrouso, G. Hereditary Vitamin D-resistant Rickets in Greek Children: Genotype, Phenotype, and Long-term Response to Treatment. J. Pediatr. Endocrinol. Metab. 2007, 20, 425–430, doi:10.1515/jpem.2007.20.3.425.

98. Malloy, P.J.; Wang, J.; Srivastava, T.; Feldman, D. Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Mol. Genet. Metab. 2010, 99, 72–79, doi:10.1016/j.ymgme.2009.09.004.

99. Nicolaidou, P.; Papadopoulou, A.; Georgouli, H.; Matsinos, Y.; Tsapra, H.; Fretzayas, A.; Giannoula-Karantana, A.; Kitsiou, S.; Douros, K.; Papassotiriou, I.; et al. Calcium and Vitamin D Metabolism in Hypocalcemic Vitamin D-Resistant Rickets Carriers. Horm. Res. Paediatri. 2006, 65, 83–88, doi:10.1159/000091043.

100. Papadopoulou, A.; Bountouvi, E.; Gole, E.; Doulergeraki, A.; Tournis, S.; Papadimitriou, A.; Nicolaidou, P. Identification of a novel nonsense mutation in the ligand-binding domain of the vitamin D receptor gene and clinical description of two Greek patients with hereditary vitamin D-resistant rickets and alopecia. Horm. Res. Paediatri. 2014, 82, 206–212, doi:10.1159/000362618.

101. Akinç, A.; Dundar, I.; Kivilcim, M. The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3 Resistant Rickets. J. Clin. Res. Pediatr. Endocrinol. 2017, 9, 172–178, doi:10.4274/jcrpe.3486.

102. Lucas, J.; Badia, J.L.; Lucas, E.; Remon, A. Cinacalcet treatment experience in hereditary vitamin D resistant rickets. J. Pediatr. Endocrinol. Metab. 2020, 33, 313–318, doi:10.1515/jpem-2019-0258.

103. Hochberg, Z.; Benderli, A.; Levy, J.; Vardi, P.; Weissman, Y.; Chen, T.; Feldman, D. 1,25-Dihydroxyvitamin D resistance, rickets, and alopecia. Am. J. Med. 1984, 77, 801–811, doi:10.1016/0002-9344(84)90516-3.

104. Xu, H.; Bai, L.; Collins, J.F.; Ghishan, F.K. Age-dependent regulation of rat intestinal type Ib sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3). Am. J. Physiol. Cell Physiol. 2002, 282, C487–C493, doi:10.1152/ajpcell.00412.2001.

105. Biber, J.; Hernando, N.; Forster, I. Phosphate transporters and their function. Annu. Rev. Physiol. 2013, 75, 535–550, doi:10.1146/annurev-physiol-030212-183748.

106. Goyal, R.; Jalal, I. Hyperphosphatemia; StatPearls: Treasure Island, FL, USA, 2020.

107. Blaine, J.; Okamura, K.; Giral, H.; Breusegem, S.; Caldas, Y.; Millard, A.; Barry, N.; Levi, M. PTH-induced internalization of apical membrane NaPi2a: Role of actin and myosin VI. Am. J. Physiol. Cell Physiol. 2009, 297, C1339–C1346, doi:10.1152/ajpcell.00260.2009.

108. Centeno, P.; Herberger, A.; Mun, H.-C.; Tu, C.; Nemeth, E.F.; Chang, W.; Conigrave, A.D.; Ward, D.T. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat. Commun. 2019, 10, 4693, doi:10.1038/s41467-019-12299-9.

109. Katai, K.; Miyamoto, K.; Kishida, S.; Segawa, H.; Nii, T.; Tanaka, H.; Tani, Y.; Arai, H.; Tatsumi, S.; Morita, K.; et al. Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem. J. 1999, 343, 705–712.

110. Bacchetta, J.; Bardet, C.; Prie, D. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism 2020, 103, 153865, doi:10.1016/j.metabol.2019.01.006.

111. Kaludjerovic, J.; Komaba, H.; Sato, T.; Erben, R.G.; Baron, R.; Olausson, H.; Larsson, T.E.; Lanske, B. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J. 2017, 31, 2050–2064, doi:10.1096/fj.201601063R.

112. Bouillon, R.; Carmellet, G.; Verlinden, L.; van Etten, E.; Verslype, A.; Loader, H.E.; Lieben, L.; Mathieu, C.; Demay, M. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr. Rev. 2008, 29, 726–776, doi:10.1210/er.2008-0004.

113. Sprague, S.M.; Wetmore, J.B.; Gurevich, K.; Da Roza, G.; Buertker, J.; Reiner, M.; Goodman, W.; Cooper, K. Effect of Cinacalcet and Vitamin D Analogos on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 2015, 10, 1021–1030, doi:10.2215/CJN.03270314.

114. Hori, M.; Kinoshita, Y.; Taguchi, M.; Fukumoto, S. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J. Bone Miner. Metab. 2015, 34, 132–139, doi:10.1007/s00774-015-0651-9.

115. Gattinoni, J.; Bates, C.; Twombly, K.; Dwarkanathan, V.; Robinson, M.L.; Goetz, R.; Mohammadi, M.; Baum, M. FGF23 decreases renal NaPi2a and NaPi2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Renal. Physiol. 2009, 297, F282–F291, doi:10.1152/ajpren.90742.2008.

116. Kinoshita, Y.; Fukumoto, S. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocr. Rev. 2018, 39, 274–291, doi:10.1210/er.2017-00220.

117. Hassan, A.; Durlacher, K.; Silver, J.; Naveh-Many, T.; Levi, R. The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. Am. J. Physiol. Renal. Physiol. 2016, 310, F217–F221, doi:10.1152/ajprenal.00332.2015.

118. Wohrle, S.; Bonny, O.; Beluch, N.; Gaulis, S.; Stamm, C.; Scheibler, M.; Muller, M.; Kinzel, B.; Thueri, A.; Brueggen, J.; et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J. Bone Miner. Res. 2011, 26, 2486–2497, doi:10.1002/jbmr.478.

119. Zhang, X.; Ibrahim, O.A.; Olsen, S.K.; Umemori, H.; Mohammadi, M.; Ornitz, D.M. Receptor Specificity of the Fibroblast Growth Factor Family. J. Biol. Chem. 2006, 281, 15694–15700, doi:10.1074/jbc.M601252200.
120. Kuro-o, M.; Matsumura, Y.; Aizawa, H.; Kawaguchi, H.; Suga, T.; Utisugi, T.; Ohyama, Y.; Kurabayashi, M.; Kaname, T.; Kume, E.; et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390, 45–51, doi:10.1038/36285.

121. Urakawa, I.; Yamazaki, Y.; Shimada, T.; Iijima, K.; Hasegawa, H.; Okawa, K.; Fujita, T.; Fukumoto, S.; Yamashita, T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444, 770–774, doi:10.1038/nature05315.

122. Matsumura, Y.; Aizawa, H.; Shiraki-Iida, T.; Nagai, R.; Kuro-O, M.; Nabeshima, Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 1998, 242, 626–630, doi:10.1006/bbrc.1997.8019.

123. Andrukhova, O.; Bayer, J.; Schuler, C.; Zeitz, U.; Murali, S.K.; Ada, S.; Alvarez-Pez, J.M.; Smorodchenko, A.; Erben, R.G. Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis. J. Bone Miner. Res. 2017, 32, 2049–2061, doi:10.1002/jbmr.3195.

124. Kuro-o, M. Klotho and aging. Biochim. Biophys. Acta 2009, 1790, 1049–1058, doi:10.1016/j.bbagen.2009.02.005.

125. Wagner, C.A.; Rubio-Aliaga, I.; Hernando, N. Renal phosphate handling and inherited disorders of phosphate reabsorption: An update. Pediatr. Nephrol. 2019, 34, 549–559, doi:10.1007/s00467-017-3873-3.

126. Tiede, M.; Modai, D.; Samuel, R.; Arie, R.; Halabe, A.; Bab, I.; Gabizon, D.; Liberman, U.A. Hereditary Hypophosphatemic Rickets with Hypercalcemia. N. Engl. J. Med. 1985, 312, 611–617, doi:10.1056/NEJM1985030731212003.

127. Bergwitz, C.; Roslin, N.M.; Tiede, M.; Loredo-Osti, J.C.; Bastpe, M.; Abu-Zahra, H.; Frappier, D.; Burkett, K.; Carpenter, T.O.; Anderson, D.; et al. SLC3A4 mutations in patients with hereditary hypophosphatemic rickets with hypercalcemia predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 2006, 78, 179–192, doi:10.1086/499409.

128. Lorenz-Depiereux, B.; Benet-Pages, A.; Eckstein, G.; Tenenbaum-Rakover, Y.; Wagenstaller, J.; Tiosano, D.; Cershoni-Baruch, R.; Albers, N.; Lichtner, P.; Schnabel, D.; et al. Hereditary hypophosphatemic rickets with hypercalcemia is caused by mutations in the sodium-phosphate cotransporter gene SLC3A4. Am. J. Hum. Genet. 2006, 78, 193–201, doi:10.1086/499410.

129. Bergwitz, C.; Miyamoto, K.I. Hereditary hypophosphatemic rickets with hypercalcemia: Pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch. 2019, 471, 149–163, doi:10.1007/s00424-018-2184-2.

130. Chen, A.; Ro, H.; Mundra, V.R.R.; Joseph, K.; Brenner, D.; Carpenter, T.O.; Rizk, D.V.; Bergwitz, C. Description of 5 Novel SLC3A4/NPT2c Mutations Causing Hereditary Hypophosphatemic Rickets with Hypercalcemia. Kidney Int. Rep. 2019, 4, 1179–1186, doi:10.1016/j.ekir.2019.05.004.

131. Ichikawa, S.; Imel, E.A.; Kreiter, M.L.; Yu, X.; Mackenzie, D.S.; Sorenson, A.H.; Goetz, R.; Mohammadi, M.; White, K.E.; Econs, M.J. A homozygous missense mutation in human KLOTHO causes severe tumor calcinosis. J. Musculoskeletal Neuronal Interact 2007, 7, 318–319.

132. Dasgupta, D.; Wei, M.J.; Reyes, M.; Li, Y.; Simm, P.J.; Sharma, A.; Schlingmann, K.P.; Janner, M.; Biggin, A.; Lazier, J.; et al. Mutations in SLC3A4/NPT2c are associated with kidney stones and nephrocalcinosis. J. Am. Soc. Nephrol. 2014, 25, 2366–2375, doi:10.1681/ASN.2013101085.

133. Kremke, B.; Bergwitz, C.; Ahrens, W.; Schutt, S.; Schumacher, M.; Wagner, V.; Holterhus, P.M.; Juppner, H.; Hiort, O. Hypophosphatemic rickets with hypercalcemia due to mutation in SLC3A4/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp. Clin. Endocrinol. Diabetes 2009, 117, 49–56, doi:10.1055/s-2008-1076716.

134. Yavropoulou, M.P.; Kotsa, K.; Gotzamani Psarrakou, A.; Papazisi, A.; Tranga, T.; Ventis, S.; Yovos, J.G. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: Case report and brief literature review. Hormones 2010, 9, 274–278, doi:10.14330/hormones.2010.0027.

135. Carpenter, T.O.; Imel, E.A.; Holm, I.A.; Jan de Beur, S.M.; Insogna, K.L. A clinician’s guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26, 1381–1388, doi:10.1002/jbmr.340.

136. Ruchon, A.F.; Tenenhouse, H.S.; Marcinkiewicz, M.; Siegfried, G.; Aubin, J.E.; DesGroseillers, L.; Crine, P.; Boileau, G. Developmental Expression and Tissue Distribution of Phex Protein: Effect of the Hyp Mutation and Relationship to Bone Markers. J. Bone Miner. Res. 2000, 15, 1440–1450, doi:10.1359/jbmr.2000.15.8.1440.

137. Šrůvastava, T.; Alon, U.S. Cinacalcet as adjunctive therapy for hereditary 1.25-dihydroxyvitamin D-resistant rickets. J. Bone Miner. Res. 2013, 28, 992–996, doi:10.1002/jbmr.1838.

138. Alon, U.S.; Jarka, D.; Monachino, P.J.; VanSickle, J.S.; Srůvastava, T. Cinacalcet as an alternative to phosphate therapy in X-linked hypophosphatemic rickets. Clin. Endocrinol. 2017, 87, 114–116, doi:10.1111/cen.13346.

139. Lamb, Y.N. Burosumab: First Global Approval. Drugs 2018, 75, 708–714, doi:10.1007/s40265-018-0905-7.

140. Florenzano, P.; Hartley, I.R.; Jimenez, M.; Roszko, K.; Gafni, R.I.; Collins, M.T. Tumor-Induced Osteomalacia. Calcif. Tissue Int. 2021, 108, 128–142, doi:10.1007/s00223-020-00691-6.

141. Imel, E.A.; Glorieux, F.H.; Whyte, M.P.; Munns, C.F.; Ward, L.M.; Nilsson, O.; Simmons, J.H.; Padidela, R.; Namba, N.; Cheong, H.I.; et al. Burosumab versus conventional therapy in children with X-linked hypophosphatemia: A randomised, controlled, open-label, phase 3 trial. Lancet 2019, 393, 2416–2427, doi:10.1016/S0140-6736(19)30654-3.

142. Shimada, T.; Muto, T.; Urakawa, I.; Yoneya, T.; Yamazaki, Y.; Okawa, K.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Yamashita, T. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143, 3179–3182, doi:10.1210/endo.143.8.8795.

143. Gattineni, J.; Baum, M. Genetic disorders of phosphate regulation. Pediatr. Nephrol. 2012, 27, 1477–1487, doi:10.1007/s00467-012-2103-2.

144. Gohil, A.; Imel, E.A. FGF23 and Associated Disorders of Phosphate Wasting. Pediatr. Endocrinol. Rev. 2019, 17, 17–34, doi:10.17458/per.voll7.2019.g1.fgf23anddisordersphosphate.
145. Liu, C.; Zhao, Z.; Wang, O.; Li, M.; Xing, X.; Hsieh, E.; Fukumoto, S.; Jiang, Y.; Xia, W. Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature. *Calcif. Tissue Int.* 2019, 106, 476–486, doi:10.1007/s00223-019-00597-y.

146. Imel, E.A.; Hui, S.L.; Econs, M.J. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. *J. Bone Miner. Res.* 2007, 22, 520–526, doi:10.1359/jbmr.070107.

147. Imel, E.A.; Peacock, M.; Gray, A.K.; Padgett, L.R.; Hui, S.L.; Econs, M.J. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. *J. Clin. Endocrinol. Metab.* 2011, 96, 3541–3549, doi:10.1210/jc.2011-1239.

148. Imel, E.A.; Liu, Z.; Coffman, M.; Acton, D.; Mehta, R.; Econs, M.J. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients with Autosomal Dominant Hypophosphatemic Rickets. *J. Bone Miner. Res.* 2020, 35, 231–238, doi:10.1002/jbmr.3878.

149. Athonvarangkul, D.; Insogna, K.L. New Therapies for Hypophosphatemia-Related to FGF23 Excess. *Calcif. Tissue Int.* 2021, 108, 143–157, doi:10.1007/s00223-020-01703-3.

150. Kuthiriyol, S.; Yesodharan, D.; Ghosh, A.; White, K.E.; Nampoothiri, S. Osteoglophonic Dysplasia: Phenotypic and Radiological Clues. *J. Pediatr. Genet.* 2017, 6, 247–251, doi:10.1055/s-0037-1602816.

151. Courage, C.; Jackson, C.B.; Owczarek-Lipska, M.; Jamsheer, A.; Sovinska-Seidler, A.; Piotrowicz, M.; Jakubowski, L.; Dalleves, F.; Riesch, E.; Neidhardt, J.; et al. Novel synonymous and missense variants in FGFR1 causing Hartsfield syndrome. *Am. J. Med. Genet. A* 2019, 179, 2447–2453, doi:10.1002/ajmg.a.61354.

152. Lorenz-Depiereux, B.; Bastepe, M.; Benet-Pagès, A.; Amyere, M.; Wagenstaller, J.; Müller-Barth, U.; Badenhoop, K.; Kaiser, S.M.; Rittmaster, R.S.; Shlossberg, A.H.; et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. *Nat. Genet.* 2006, 38, 1248–1250, doi:10.1038/ng1868.

153. Levy-Litan, V.; Hershkovitz, E.; Avizov, L.; Leventhal, N.; Bercovich, D.; Chalifa-Caspi, V.; Manor, E.; Buriakovsky, S.; Hadad, Y.; Goding, J.; et al. Autosomal-Recessive Hypophosphatemic Rickets Is Associated with an Inactivation Mutation in the ENPP1 Gene. *Am. J. Hum. Genet.* 2010, 86, 273–278, doi:10.1016/j.ajhg.2010.01.010.

154. Negri, A.L. Hereditary hypophosphatemias: New genes in the bone-kidney axis. *Nephrology* 2012, 17, 317–320, doi:10.1111/j.1440-1797.2007.00824.x.

155. Lu, Y.; Yuan, B.; Qin, C.; Cao, Z.; Xie, Y.; Dallas, S.L.; McKee, M.D.; Drezner, M.K.; Bonewald, L.F.; Feng, J.Q. The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment. *J. Bone Miner. Res.* 2011, 26, 331–340, doi:10.1002/jbmr.226.

156. Ni, X.; Li, X.; Zhang, Q.; Liu, C.; Gong, Y.; Wang, O.; Li, M.; Xing, X.; Jiang, Y.; Xia, W. Clinical Characteristics and Bone Features of Autosomal Recessive Hypophosphatemic Rickets Type 1 in Three Chinese Families: Report of Five Chinese Cases and Review of the Literature. *Calcif. Tissue Int.* 2020, 107, 636–648, doi:10.1007/s00223-020-00755-7.

157. Zimmermann, H.; Zebsch, M.; Sträter, N. Cellular function and molecular structure of ecto-nucleotidases. *Purinergic Signal.* 2012, 8, 497–502, doi:10.1007/s11202-012-9309-4.

158. Rutsch, F.; Ruf, N.; Vaingankar, S.; Tolliat, M.R.; Suk, A.; Höhne, W.; Schauer, G.; Lehmann, M.; Roscioli, T.; Schnabel, D.; et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. *Nat. Genet.* 2003, 34, 379–381, doi:10.1038/ng1221.

159. Kotwal, A.; Ferrer, A.; Kumar, R.; Singh, R.J.; Murthy, V.; Schultz-Rogers, L.; Zimmermann, M.; Lanpher, B.; Zimmerman, K.; Stabach, P.R.; et al. Clinical and Biochemical Phenotypes in a Family with ENPP1 Mutations. *J. Bone Miner. Res.* 2020, 35, 662–670, doi:10.1002/jbmr.3938.

160. Rafaelsen, S.H.; Raeder, H.; Fagerheim, A.K.; Knappskog, P.; Carpenter, T.O.; Johansson, S.; Bjerknes, R. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. *J. Bone Miner. Res.* 2013, 28, 1378–1385, doi:10.1002/jbmr.1850.

161. Tagliabucchi, V.S.; Engel, J.L.; Wiley, S.E.; Xiao, J.; Gonzalez, D.J.; Appaiah, H.N.; Koller, A.; Nizet, V.; White, K.E.; Dixon, J.E. Dynamic regulation of FGF23 by FAM20C phosphorylation, GalNAC-T3 glycosylation, and furin proteolysis. *Proc. Natl. Acad. Sci. USA* 2014, 111, 5520–5525, doi:10.1073/pnas.1402218111.

162. Brownstein, C.A.; Adler, F.; Nelson-Williams, C.; Iijima, J.; Li, P.; Imura, A.; Nabetsuma, Y.; Reyes-Mugica, M.; Carpenter, T.O.; Lifton, R.P. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. *Proc. Natl. Acad. Sci. USA* 2008, 105, 3455–3460, doi:10.1073/pnas.0712361105.

163. Wagner, C.A.; Rubio-Aliaga, I.; Biber, J.; Hernando, N. Genetic diseases of renal phosphate handling. *Nephrol. Dial. Transpl.* 2014, 29 (Suppl. 4), iv45–iv54, doi:10.1093/ndt/gfu217.